These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31884574)

  • 1. Risk Factors of Metabolic Syndrome Among Patients Receiving Antipsychotics: A Retrospective Study.
    Hammoudeh S; Al Lawati H; Ghuloum S; Iram H; Yehya A; Becetti I; Al-Fakhri N; Ghabrash H; Shehata M; Ajmal N; Amro I; Safdar H; Eltorki Y; Al-Amin H
    Community Ment Health J; 2020 May; 56(4):760-770. PubMed ID: 31884574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prevalence of metabolic syndrome in patients receiving antipsychotics in Qatar: a cross sectional comparative study.
    Hammoudeh S; Ghuloum S; Mahfoud Z; Yehya A; Abdulhakam A; Al-Mujalli A; Al-Zirie M; Abdel Rahman MO; Godwin A; Younes N; Hani Y; Mook-Kanamori D; Mook-Kanamori M; El Sherbiny R; Al-Amin H
    BMC Psychiatry; 2018 Mar; 18(1):81. PubMed ID: 29587717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration.
    Shi L; Ascher-Svanum H; Chiang YJ; Zhao Y; Fonseca V; Winstead D
    BMC Psychiatry; 2009 Dec; 9():80. PubMed ID: 20021664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic syndrome in schizophrenia - who is more to blame: FGA polypharmacy or clozapine monotherapy?
    Softic R; Sutovic A; Avdibegovic E; Osmanović E; Bećirović E; Hajdukov MM
    Psychiatr Danub; 2015 Dec; 27(4):378-84. PubMed ID: 26609650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
    Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
    J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Metabolic Syndrome in Drug-Naive Adolescents After 12 Months of Second-Generation Antipsychotic Treatment.
    Sjo CP; Stenstrøm AD; Bojesen AB; Frølich JS; Bilenberg N
    J Child Adolesc Psychopharmacol; 2017 Dec; 27(10):884-891. PubMed ID: 28783382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic syndrome in schizophrenia: a comparative study of antipsychotic-free/naïve and antipsychotic-treated patients from India.
    Pallava A; Chadda RK; Sood M; Lakshmy R
    Nord J Psychiatry; 2012 Jun; 66(3):215-21. PubMed ID: 22017264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signs and symptoms associated with the metabolic syndrome in psychiatric inpatients receiving antipsychotics: a retrospective chart review.
    Goethe JW; Szarek BL; Caley CF; Woolley SB
    J Clin Psychiatry; 2007 Jan; 68(1):22-8. PubMed ID: 17284126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of a computerized best practice alert system in an outpatient setting on metabolic monitoring in patients on second-generation antipsychotics.
    Cohen S; Bostwick JR; Marshall VD; Kruse K; Dalack GW; Patel P
    J Clin Pharm Ther; 2020 Dec; 45(6):1398-1404. PubMed ID: 32767599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs.
    Falissard B; Mauri M; Shaw K; Wetterling T; Doble A; Giudicelli A; De Hert M
    Int Clin Psychopharmacol; 2011 Nov; 26(6):291-302. PubMed ID: 21876442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Metabolic testing rates after initiation of antipsychotic treatment in persons initially treated by conventional mood-stabilizers].
    Verdoux H; Gaudron Y; Auleley GR; Deligne J; Blum-Boisgard C; Thiébaut A; Tournier M
    Encephale; 2013 May; 39 Suppl 1():S22-8. PubMed ID: 23246328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Metabolic Monitoring of Youths Treated with Second-Generation Antipsychotics 5 Years after Publication of the CAMESA Guidelines Are We Making Progress? Surveillance Métabolique à Long Terme des Jeunes Traités par Antipsychotiques de Deuxième Génération, Cinq ans Après la publication des Lignes Directrices Camesa: Faisons-Nous des Progrès?
    Jazi S; Ben-Amor L; Abadie P; Menard ML; Choquette R; Berthiaume C; Mottron L; Ilies D
    Can J Psychiatry; 2021 Jul; 66(7):645-656. PubMed ID: 33243011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a Community Mental Health Centre.
    Tarricone I; Casoria M; Gozzi BF; Grieco D; Menchetti M; Serretti A; Ujkaj M; Pastorelli F; Berardi D
    BMC Psychiatry; 2006 Mar; 6():11. PubMed ID: 16542430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics.
    Krane-Gartiser K; Breum L; Glümrr C; Linneberg A; Madsen M; Køster A; Jepsen PW; Fink-Jensen A
    Nord J Psychiatry; 2011 Oct; 65(5):345-52. PubMed ID: 21428861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic syndrome in patients with severe mental illness undergoing psychiatric rehabilitation receiving high dose antipsychotic medication.
    Ravindranath BV
    Indian J Psychol Med; 2012 Jul; 34(3):247-54. PubMed ID: 23439746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effect of Long-Term Second-Generation Antipsychotics Use on the Metabolic Syndrome Parameters in Jordanian Population.
    Abo Alrob O; Alazzam S; Alzoubi K; Nusair MB; Amawi H; Karasneh R; Rababa'h A; Nammas M
    Medicina (Kaunas); 2019 Jun; 55(7):. PubMed ID: 31261805
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study.
    Gründer G; Heinze M; Cordes J; Mühlbauer B; Juckel G; Schulz C; Rüther E; Timm J;
    Lancet Psychiatry; 2016 Aug; 3(8):717-729. PubMed ID: 27265548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: a cross-sectional assessment of a primary health care database.
    Sicras-Mainar A; Blanca-Tamayo M; Rejas-Gutiérrez J; Navarro-Artieda R
    Eur Psychiatry; 2008 Mar; 23(2):100-8. PubMed ID: 17904825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using an Integrated Care Pathway for Late-Life Schizophrenia Improves Monitoring of Adverse Effects of Antipsychotics and Reduces Antipsychotic Polypharmacy.
    Abdool PS; Supasitthumrong T; Patel K; Mulsant BH; Rajji TK
    Am J Geriatr Psychiatry; 2019 Jan; 27(1):84-90. PubMed ID: 30396766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.